The presence of flurone doesn't mean another variation of COVID-19 || health tips by seemab

In the first case distinguished in the country, the Ministry of Health of the Nation gave an assertion to explain that it doesn't address an uncommon circumstance with regards to the Covid pandemic, since it is normal to see co-location of two respiratory infections and that this doesn't mean the presence of another variation or strain of the infection that causes COVID-19 illness.

Also, they clarified that "the co-course of COVID-19 and flu can happen especially in the fall and cold weather months yet that, starting at the last a long time of 2021, the movement of the flu infection is expanding in the northern half of the globe and in certain nations of the Andean subregion and the Southern Cone, so given the current elements of dissemination viral co-diseases are probably going to be distinguished."

Nonetheless, they noticed that Since the presentation of SARS-CoV-2 in the Americas locale, flu activity has been low.

In that sense, from the service it was accounted for that, throughout the most recent year, the commonness of flu coinfection among patients with COVID-19 has been assessed at 0.8%, albeit, later on, this might change contingent upon the transmission and course of the different respiratory infections.

Its name "flurona" is because of the blend of the names of the infections in English ("Flu" and "Covid"). "Albeit uncommon, coinfections of two respiratory infections can happen", he had remarked to Infobae Gonzalo Pérez Marc, clinical analyst and head of the examination and educating at the Maternal and Child Unit of the Central Military Hospital in Buenos Aires.

For Pérez Marc, from next March with the appearance of fall, there could be a more serious danger of more instances of "fleuron" co-contaminations in South America. This has to do with the way that the seasonal infection courses more in the fall and winter and could build its effect in 2022. He explained that for treatment, side effects should be controlled. "Assuming that there are inconveniences, individuals might require hospitalization and sometimes antiviral medications are given," he said.

                   In this sense, Dr. Edward Lopez, head of the pediatric infectology course at the Faculty of Medicine of the University of Buenos Aires and leader of the Argentine Society of Pediatric Infectious Diseases, when counseled by Infobae had remarked that "Treatment of coinfection will rely upon the patient's circumstance. In any case, on a basic level, it is dealt with more control because of the expanded danger of aspiratory inconveniences. At last, in these patients, oseltamivir could be demonstrated inside the initial 48 hours."

"Similarly as with COVID-19, there is immunization against flu, so applying it, particularly in the period of low temperatures and expanded cases, is the most ideal way to forestall contamination. Also, later on almost certainly, the two antibodies, against flu and against SARS-CoV-2, will be applied in a similar portion, "clarified Dr. Alberto Cormillot.